The BCL-2 arbiters of apoptosis and their growing role as cancer targets

Cell Death and Differentiation

Volumn 25, Issue 1, 2018, Pages 27-36

  Adams, Jerry M ^a,b   Cory, Suzanne ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BH3 PROTEIN; PROTEIN BCL 2; PROTEIN INHIBITOR; PROTEIN MCL 1; PROTEIN P53; VENETOCLAX; APOPTOSIS REGULATORY PROTEIN; BCL2 PROTEIN, HUMAN; FUSED HETEROCYCLIC RINGS; SULFONAMIDE;

APOPTOSIS; ARTICLE; BIOMIMETICS; CANCER THERAPY; CELL DEATH; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DISEASE COURSE; DRUG ACTIVITY; DRUG SCREENING; HUMAN; MALIGNANT NEOPLASM; NONHUMAN; PRECLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; SURVIVAL; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; METABOLISM; MITOCHONDRIAL MEMBRANE; NEOPLASM; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; HUMANS; MITOCHONDRIAL MEMBRANES; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES;

EID: 85041401304     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2017.161     Document Type: Article

References (132)

1. Croce C. miR15/16 and Bcl2: from gene discovery to treatment. Cell Death Differ 2018; 25: 21-26.
2. Strasser A, Vaux DL. Bcl2 and cell death from an evolutionary perspective. Cell Death Differ 2018; 25: 13-20.
3. Opferman J. BCL-2 family in development. Cell Death Differ 2018; 25: 37-45.
4. Andrews DW. Bcl-2 family proteins: Changing partners in the dance towards death. Cell Death Differ 2018; 25: 65-80.
5. Letai A. Why do BCL-2 inhibitors work and where should we use them in the clinic? Cell Death Differ 2018; 25: 56-64.
6. Green DR. MOMP, from cytochrome c and Smac to unified theory of Bcl-2 function to BAX/BAK activation to BOK. Cell Death Differ 2018; 25: 46-55.
7. Correia C, Lee SH, Meng XW, Vincelette ND, Knorr KL, Ding H et al. Emerging understanding of Bcl-2 biology: implications for neoplastic progression and treatment. Biochim Biophys Acta 2015; 1853: 1658-1671.
8. Cory S, Roberts A, Colman PM, Adams JM. Targeting BCL-2-like proteins to kill cancer cells. Trends Cancer 2016; 2: 443-460.
9. Ashkenazi A, Fairbrother WJ, Leverson JD, Souers AJ. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nat Rev Drug Discov 2017; 16: 273-284.
10. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 2014; 15: 49-63.
11. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wideranging implications in tissue kinetics. Br J Cancer 1972; 26: 239-257.
12. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335: 440-442.
13. McDonnell TJ, Deane N, Platt FM, Nuñez G, Jaeger U, McKearn JP et al. bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989; 57: 79-88.
14. Strasser A, Whittingham S, Vaux DL, Bath ML, Adams JM, Cory S et al. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci USA 1991; 88: 8661-8665.
15. Sentman CL, Shutter JR, Hockenbery D, Kanagawa O, Korsmeyer SJ. bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 1991; 67: 879-888.
16. Strasser A, Harris AW, Cory S. Bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship. Cell 1991; 67: 889-899.
17. Strasser A, Harris AW, Bath ML, Cory S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 1990; 348: 331-333.
18. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992; 69: 119-128.
19. Strasser A, Elefanty AG, Harris AW, Cory S. Progenitor tumours from Em-bcl-2-myc transgenic mice have lymphomyeloid differentiation potential and reveal developmental differences in cell survival. EMBO J 1996; 15: 3823-3834.
20. Limpens J, Stad R, Vos C, de Vlaam C, de Jong D, van Ommen G-JB et al. Lymphomaassociated translocation t(14;18) in blood B cells of normal individuals. Blood 1995; 85: 2528-2536.
21. Egle A, Harris AW, Bath ML, O'Reilly L, Cory S. VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia. Blood 2004; 103: 2276-2283.
22. Lindsten T, Ross AJ, King A, Zong W, Rathmell JC, Shiels HA et al. The combined functions of proapoptotic Bcl-2 family members Bak and Bax are essential for normal development of multiple tissues. Mol Cell 2000; 6: 1389-1399.
23. Strasser A, Cory S, Adams JM. Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J 2011; 30: 3667-3683.
24. Happo L, Strasser A, Cory S. BH3-only proteins in apoptosis at a glance. J Cell Sci 2012; 125: 1081-1087.
25. Egle A, Harris AW, Bouillet P, Cory S. Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci USA 2004; 101: 6164-6169.
26. L, an inhibitor of programmed cell death. Nature 1996; 381: 335-341.
27. L/Bim fragment complex: Implications for Bim function. Immunity 2003; 19: 341-352.
28. Suzuki M, Youle RJ, Tjandra N. Structure of Bax: coregulation of dimer formation and intracellular localization. Cell 2000; 103: 645-654.
29. Kvansakul M, Hinds MG. The Bcl-2 family: structures, interactions and targets for drug discovery. Apoptosis 2015; 20: 136-150.
30. L-Bak peptide complex: recognition between regulators of apoptosis. Science 1997; 275: 983-986.
31. Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 2003; 426: 671-676.
32. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005; 17: 393-403.
33. Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 2005; 17: 525-535.
34. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005; 19: 1294-1305.
35. Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007; 315: 856-859.
36. Edlich F, Banerjee S, Suzuki M, Cleland MM, Arnoult D, Wang C et al. Bcl-x(L) retrotranslocates Bax from the mitochondria into the cytosol. Cell 2011; 145: 104-116.
37. Todt F, Cakir Z, Reichenbach F, Emschermann F, Lauterwasser J, Kaiser A et al. Differential retrotranslocation of mitochondrial Bax and Bak. EMBO J 2015; 34: 67-80.
38. Cheng EH, Sheiko TV, Fisher JK, Craigen WJ, Korsmeyer SJ. VDAC2 inhibits BAK activation and mitochondrial apoptosis. Science 2003; 301: 513-517.
39. Roy SS, Ehrlich AM, Craigen WJ, Hajnoczky G. VDAC2 is required for truncated BIDinduced mitochondrial apoptosis by recruiting BAK to the mitochondria. EMBO Rep 2009; 10: 1341-1347.
40. Ma SB, Nguyen TN, Tan I, Ninnis R, Iyer S, Stroud DA et al. Bax targets mitochondria by distinct mechanisms before or during apoptotic cell death: a requirement for VDAC2 or Bak for efficient Bax apoptotic function. Cell Death Differ 2014; 21: 1925-1935.
41. Czabotar PE, Westphal D, Dewson G, Ma S, Hockings C, Fairlie WD et al. Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis. Cell 2013; 152: 519-531.
42. Moldoveanu T, Grace CR, Llambi F, Nourse A, Fitzgerald P, Gehring K et al. BID-induced structural changes in BAK promote apoptosis. Nat Struct Mol Biol 2013; 20: 589-597.
43. Brouwer JM, Westphal D, Dewson G, Robin AY, Uren RT, Bartolo R et al. Bak core and latch domains separate during activation, and freed core domains form symmetric homodimers. Mol Cell 2014; 55: 938-946.
44. Robin AY, Krishna Kumar K, Westphal D, Wardak AZ, Thompson GV, Dewson G et al. Crystal structure of Bax bound to the BH3 peptide of Bim identifies important contacts for interaction. Cell Death Dis 2015; 6: e1809.
45. Alsop AE, Fennell SC, Bartolo RC, Tan IK, Dewson G, Kluck RM. Dissociation of Bak alpha1 helix from the core and latch domains is required for apoptosis. Nat Commun 2015; 6: 6841.
46. Dewson G, Kratina T, Sim HW, Puthalakath H, Adams JM, Colman PM et al. To trigger apoptosis Bak exposes its BH3 domain and homo-dimerizes via BH3:grooove interactions. Mol Cell 2008; 30: 369-380.
47. Dewson G, Ma S, Frederick P, Hockings C, Tan I, Kratina T et al. Bax dimerizes via a symmetric BH3:groove interface during apoptosis. Cell Death Differ 2012; 19: 661-670.
48. O'Neill KL, Huang K, Zhang J, Chen Y, Luo X. Inactivation of prosurvival Bcl-2 proteins activates Bax/Bak through the outer mitochondrial membrane. Genes Dev 2016; 30: 973-988.
49. George NM, Evans JJ, Luo X. A three-helix homo-oligomerization domain containing BH3 and BH1 is responsible for the apoptotic activity of Bax. Genes Dev 2007; 21: 1937-1948.
50. Dewson G, Kratina T, Czabotar P, Day CL, Adams JM, Kluck RM. Bak activation for apoptosis involves oligomerization of dimers via their alpha6 helices. Mol Cell 2009; 36: 696-703.
51. Ma S, Hockings C, Anwari K, Kratina T, Fennell S, Lazarou M et al. Assembly of the Bak apoptotic pore: a critical role for the Bak protein alpha6 helix in the multimerization of homodimers during apoptosis. J Biol Chem 2013; 288: 26027-26038.
52. Aluvila S, Mandal T, Hustedt E, Fajer P, Choe JY, Oh KJ. Organization of the mitochondrial apoptotic BAK pore: oligomerization of the BAK homodimers. J Biol Chem 2014; 289: 2537-2551.
53. Iyer S, Bell F, Westphal D, Anwari K, Gulbis J, Smith BJ et al. Bak apoptotic pores involve a flexible C-terminal region and juxtaposition of the C-terminal transmembrane domains. Cell Death Differ 2015; 22: 1665-1675.
54. Zhang Z, Subramaniam S, Kale J, Liao C, Huang B, Brahmbhatt H et al. BH3-in-groove dimerization initiates and helix 9 dimerization expands Bax pore assembly in membranes. EMBO J 2016; 35: 208-236.
55. Uren RT, O'Hely M, Iyer S, Bartolo R, Shi MX, Brouwer JM et al. Disordered clusters of Bak dimers rupture mitochondria during apoptosis. Elife 2017; 6: e19944.
56. Westphal D, Dewson G, Menard M, Frederick P, Iyer S, Bartolo R et al. Apoptotic pore formation is associated with in-plane insertion of Bak or Bax central helices into the mitochondrial outer membrane. Proc Natl Acad Sci USA 2014; 111: E4076-E4085.
57. Bleicken S, Jeschke G, Stegmueller C, Salvador-Gallego R, Garcia-Saez AJ, Bordignon E. Structural model of active Bax at the membrane. Mol Cell 2014; 56: 496-505.
58. Uren RT, Iyer S, Kluck RM. Pore formation by dimeric Bak and Bax: an unusual pore? Philos Trans R Soc Lond B Biol Sci 2017; 372: 1726.
59. Annis MG, Soucie EL, Dlugosz PJ, Cruz-Aguado JA, Penn LZ, Leber B et al. Bax forms multispanning monomers that oligomerize to permeabilize membranes during apoptosis. EMBO J 2005; 24: 2096-2103.
60. Kuwana T, Olson NH, Kiosses WB, Peters B, Newmeyer DD. Pro-apoptotic Bax molecules densely populate the edges of membrane pores. Sci Rep 2016; 6: 27299.
61. Salvador-Gallego R, Mund M, Cosentino K, Schneider J, Unsay J, Schraermeyer U et al. Bax assembly into rings and arcs in apoptotic mitochondria is linked to membrane pores. EMBO J 2016; 35: 389-401.
62. Grosse L, Wurm CA, Bruser C, Neumann D, Jans DC, Jakobs S. Bax assembles into large ring-like structures remodeling the mitochondrial outer membrane in apoptosis. EMBO J 2016; 35: 402-413.
63. Beroukhim R, Mermel C, Porter D, Wei G, Raychaudhuri S, Donovan J et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010; 463: 899-905.
64. Villunger A, Michalak EM, Coultas L, Mullauer F, Bock G, Ausserlechner MJ et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 2003; 302: 1036-1038.
65. Tagawa H, Karnan S, Suzuki R, Matsuo K, Zhang X, Ota A et al. Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene 2005; 24: 1348-1358.
66. Garrison SP, Jeffers JR, Yang C, Nilsson JA, Hall MA, Rehg JE et al. Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis. Mol Cell Biol 2008; 28: 5391-5402.
67. Richter-Larrea JA, Robles EF, Fresquet V, Beltran E, Rullan AJ, Agirre X et al. Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. Blood 2010; 116: 2531-2542.
68. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10: 389-399.
69. Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 2008; 7: 989-1000.
70. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681.
71. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421-3428.
72. Lee EF, Czabotar PE, Smith BJ, Deshayes K, Zobel K, Colman PM et al. Crystal structure of ABT-737 complexed with Bcl-x(L): implications for selectivity of antagonists of the Bcl- 2 family. Cell Death Differ 2007; 14: 1711-1713.
73. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19: 202-208.
74. Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S et al. Programmed anuclear cell death delimits platelet life span. Cell 2007; 128: 1173-1186.
75. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012; 30: 488-496.
76. Wilson WH, O'Connor OA, Czuczman MS, Lacasce AS, Gerecitano JF, Leonard JP et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010; 11: 1149-1159.
77. Vandenberg CJ, Cory S. ABT-199 a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood 2013; 121: 2285-2288.
78. Lessene G, Czabotar PE, Sleebs BE, Zobel K, Lowes KL, Adams JM et al. Structureguided design of a selective BCL-XL inhibitor. Nat Chem Biol 2013; 9: 390-397.
79. Leverson JD, Phillips DC, Mitten MJ, Boghaert ER, Diaz D, Tahir SK et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med 2015; 7: 279ra240.
80. Certo M, Moore Vdel G, Nishino M, Wei G, Korsmeyer S, Armstrong SA et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006; 9: 351-365.
81. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 2007; 117: 112-121.
82. Merino D, Khaw SL, Glaser SP, Anderson DJ, Belmont LD, Wong C et al. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood 2012; 119: 5807-5816.
83. Chonghaile TN, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore VD et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 2011; 334: 1129-1133.
84. Vo TT, Ryan J, Carrasco R, Neuberg D, Rossi DJ, Stone RM et al. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell 2012; 151: 344-355.
85. Sarosiek KA, Fraser C, Muthalagu N, Bhola PD, Chang W, McBrayer SK et al. Developmental regulation of mitochondrial apoptosis by c-Myc governs age- and tissuespecific sensitivity to cancer therapeutics. Cancer Cell 2017; 31: 142-156.
86. Mason KD, Vandenberg CJ, Scott CL, Wei AH, Cory S, Huang DC et al. In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proc Natl Acad Sci USA 2008; 105: 17961-17966.
87. Roberts AW, Advani RH, Kahl BS, Persky D, Sweetenham JW, Carney DA et al. Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies. Br J Haematol 2015; 170: 669-678.
88. Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med 2016; 374: 311-322.
89. Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol 2016; 17: 768-778.
90. Anderson MA, Deng J, Seymour JF, Tam C, Kim SY, Fein J et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood 2016; 127: 3215-3224.
91. Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG et al. Phase I firstin-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol 2017; 35: 826-833.
92. Roberts AW, Huang D. Targeting BCL2 with BH3 mimetics: basic science and clinical application of venetoclax in chronic lymphocytic leukemia and related B cell malignancies. Clin Pharmacol Ther 2017; 101: 89-98.
93. Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov 2016; 6: 1106-1117.
94. Matulis SM, Gupta VA, Nooka AK, Hollen HV, Kaufman JL, Lonial S et al. Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax. Leukemia 2016; 30: 1086-1093.
95. Cervantes-Gomez F, Lamothe B, Woyach JA, Wierda WG, Keating MJ, Balakrishnan K et al. Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia. Clin Cancer Res 2015; 21: 3705-3715.
96. Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids MS et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol 2017; 18: 230-240.
97. Pollyea DA, Di Nardo C, Thirman M, Letai A, Wei A, Jonas BA et al. Results of a phase 1b study of venetoclax plus decitabine or azacitidine in untreated acute myeloid leukemia patients4= 65 years ineligible for standard induction therapy. Haematologica 2016; 101 (Supplement): 44-44.
98. Teh TC, Nguyen NY, Moujalled DM, Segal D, Pomilio G, Rijal S et al. Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1. Leukemia 2017.
99. Chan SM, Thomas D, Corces-Zimmerman MR, Xavy S, Rastogi S, Hong WJ et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med 2015; 21: 178-184.
100. Carter BZ, Mak PY, Mu H, Zhou H, Mak DH, Schober W et al. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Sci Transl Med 2016; 8: 355ra117.
101. Vaillant F, Merino D, Lee L, Breslin K, Pal B, Ritchie ME et al. Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. Cancer Cell 2013; 24: 120-129.
102. Zhang H, Guttikonda S, Roberts L, Uziel T, Semizarov D, Elmore SW et al. Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines. Oncogene 2011; 30: 1963-1968.
103. Xiao Y, Nimmer P, Sheppard GS, Bruncko M, Hessler P, Lu X et al. MCL-1 Is a key determinant of breast cancer cell survival: validation of MCL-1 dependency utilizing a highly selective small molecule inhibitor. Mol Cancer Ther 2015; 14: 1837-1847.
104. Leverson JD, Zhang H, Chen J, Tahir SK, Phillips DC, Xue J et al. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis 2015; 6: e1590.
105. Yecies D, Carlson NE, Deng J, Letai A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 2010; 115: 3304-3313.
106. Glaser S, Lee EF, Trounson E, Bouillet P, Wei A, Fairlie WD et al. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev 2012; 26: 120-125.
107. Kelly GL, Grabow S, Glaser SP, Fitzsimmons L, Aubrey BJ, Okamoto T et al. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes Dev 2014; 28: 58-70.
108. Grabow S, Delbridge AR, Valente LJ, Strasser A. MCL-1 but not BCL-XL is critical for the development and sustained expansion of thymic lymphoma in p53-deficient mice. Blood 2014; 124: 3939-3946.
109. Koss B, Morrison J, Perciavalle RM, Singh H, Rehg JE, Williams RT et al. Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia. Blood 2013; 122: 1587-1598.
110. Gong JN, Khong T, Segal D, Yao Y, Riffkin CD, Garnier JM et al. Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1. Blood 2016; 128: 1834-1844.
111. Thomas RL, Roberts DJ, Kubli DA, Lee Y, Quinsay MN, Owens JB et al. Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure. Genes Dev 2013; 27: 1365-1377.
112. Vick B, Weber A, Urbanik T, Maass T, Teufel A, Krammer PH et al. Knockout of myeloid cell leukemia-1 induces liver damage and increases apoptosis susceptibility of murine hepatocytes. Hepatology 2009; 49: 627-636.
113. Arbour N, Vanderluit JL, Le Grand JN, Jahani-Asl A, Ruzhynsky VA, Cheung EC et al. Mcl-1 is a key regulator of apoptosis during CNS development and after DNA damage. J Neurosci 2008; 28: 6068-6078.
114. Perciavalle RM, Stewart DP, Koss B, Lynch J, Milasta S, Bathina M et al. Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration. Nat Cell Biol 2012; 14: 575-583.
115. Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature 2016; 538: 477-482.
116. Merino D, Whittle JR, Vaillant F, Serrano A, Gong JN, Giner G et al. Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer. Sci Transl Med 2017; 9: 401.
117. Hughes PE The discovery and preclinical characterization of AMG 176: a first-in-class Mcl- 1 inhibitor in clinical development for multiple myeloma. Proceedings: American Association for Cancer Research Annual Meeting, Washington, DC 2017 Abstract DDT01-01.
118. Hird AW, Secrist JP, Adam A, Belmonte MA, Gangl E, Gibbons F et al. AZD5991: a potent and selective macrocyclic inhibitor of Mcl-1 for treatment of hematologic cancers. Proceedings: American Association for Cancer Research Annual Meeting, 2017. Abstract DDT01-02.
119. Zhang H, Xue J, Hessler P, Tahir SK, Chen J, Jin S et al. Genomic analysis and selective small molecule inhibition identifies BCL-X(L) as a critical survival factor in a subset of colorectal cancer. Mol Cancer 2015; 14: 126.
120. Amundson SA, Myers TG, Scudiero D, Kitada S, Reed JC, Fornace AJ Jr. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res 2000; 60: 6101-6110.
121. Kasai S, Chuma S, Motoyama N, Nakatsuji N. Haploinsufficiency of Bcl-x leads to malespecific defects in fetal germ cells: differential regulation of germ cell apoptosis between the sexes. Dev Biol 2003; 264: 202-216.
122. Adams CM, Kim AS, Mitra R, Choi JK, Gong JZ, Eischen CM. BCL-W has a fundamental role in B cell survival and lymphomagenesis. J Clin Invest 2017; 127: 635-650.
123. Print CG, Loveland KL, Gibson L, Meehan T, Stylianou A, Wreford N et al. Apoptosis regulator Bcl-w is essential for spermatogenesis but appears otherwise redundant. Proc Natl Acad Sci USA 1998; 95: 12424-12431.
124. Brien G, Trescol-Biemont MC, Bonnefoy-Berard N. Downregulation of Bfl-1 protein expression sensitizes malignant B cells to apoptosis. Oncogene 2007; 26: 5828-5832.
125. Schenk RL, Tuzlak S, Carrington EM, Zhan Y, Heinzel S, Teh CE et al. Characterisation of mice lacking all functional isoforms of the pro-survival BCL-2 family member A1 reveals minor defects in the haematopoietic compartment. Cell Death Differ 2017; 24: 534-545.
126. Gavathiotis E, Reyna DE, Bellairs JA, Leshchiner ES, Walensky LD. Direct and selective small-molecule activation of proapoptotic BAX. Nat Chem Biol 2012; 8: 639-645.
127. Zhao G, Zhu Y, Eno CO, Liu Y, Deleeuw L, Burlison JA et al. Activation of the proapoptotic Bcl-2 protein Bax by a small molecule induces tumor cell apoptosis. Mol Cell Biol 2014; 34: 1198-1207.
128. Iyer S, Anwari K, Alsop AE, Yuen WS, Huang DC, Carroll J et al. Identification of an activation site in Bak and mitochondrial Bax triggered by antibodies. Nat Commun 2016; 7: 11734.
129. Pritz JR, Wachter F, Lee S, Luccarelli J, Wales TE, Cohen DT et al. Allosteric sensitization of proapoptotic BAX. Nat Chem Biol 2017; 13: 961-967.
130. Gavathiotis E, Suzuki M, Davis ML, Pitter K, Bird GH, Katz SG et al. BAX activation is initiated at a novel interaction site. Nature 2008; 455: 1076-1081.
131. Gavathiotis E, Reyna DE, Davis ML, Bird GH, Walensky LD. BH3-triggered structural reorganization drives the activation of proapoptotic BAX. Mol Cell 2010; 40: 481-492.
132. Bleicken S, Classen M, Padmavathi PV, Ishikawa T, Zeth K, Steinhoff HJ et al. Molecular details of Bax activation, oligomerization, and membrane insertion. J Biol Chem 2010; 285: 6636-6647.